Cerus Corporation (CU2)
XDUS 
Summary
CU2 Chart
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis
Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Cerus's Record 2025 Sets It Up For Another Leg Higher
CERS' INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They've also grown their adoption across ~40 countries. INT200 received European approval and launched. They also have a US PMA filing targeted for 2026. This means CERS may soon have another hardware refresh cycle, with future kit pull-through.
Cerus Corporation (CU2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cerus Corporation ever had a stock split?
Cerus Corporation Profile
| Biotechnology Industry | Healthcare Sector | William Greenman CEO | XDUS Exchange | US1570851014 ISIN |
| US Country | 614 Employees | - Last Dividend | - Last Split | 30 Jan 1997 IPO Date |
Overview
Cerus Corporation, established in 1991 and based in Concord, California, positions itself at the forefront of the biomedical products industry with a strong focus on blood safety. The cornerstone of its operations is the development and commercialization of the INTERCEPT Blood System, a proprietary technology designed to enhance the safety of blood transfusions by reducing the presence of blood-borne pathogens in donated blood components. This innovative approach to ensuring blood safety marks Cerus Corporation as a key player in the biomedical sector, catering to an essential need in healthcare systems globally. The company's reach extends beyond the United States, touching markets in Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international territories through both direct sales forces and distributors.
Products and Services
- INTERCEPT Blood System for Platelets and Plasma: This variant of the INTERCEPT Blood System is specifically designed to inactivate pathogens present in platelets and plasma donated for transfusion purposes. By targeting these components, Cerus Corporation aims to significantly reduce the risk of transmission of blood-borne diseases through transfusions.
- INTERCEPT Blood System for Red Blood Cells: Similar to its counterparts for platelets and plasma, this system is engineered to inactivate pathogens in red blood cells intended for transfusion. Given the essential role of red blood cells in carrying oxygen to the body's tissues, ensuring their safety is critical for patient care.
- INTERCEPT Blood System for Cryoprecipitation: This system utilizes the INTERCEPT plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex. It is aimed at the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency. This application not only enhances the safety of using cryoprecipitate but also addresses critical medical situations where time and safety are of the essence.
- Pathogen Reduced Plasma, Cryoprecipitate Reduced: By applying its proprietary technology, Cerus Corporation provides pathogen-reduced plasma and cryoprecipitate solutions. These products are pivotal for patient care in situations requiring plasma or fibrinogen complex, further underscoring the company's contribution to safer transfusion practices.
